The team at Oxford Cancer Biomarkers (OCB) are pleased to announce the expansion of our ToxNav® DPYD genomics panel with the inclusion of HAPB3.
Effective from the 6th October 2020, the ToxNav® panel will contain one additional genetic variant (HAPB3; rs56038477). This variant has been shown to be associated with severe DPYD toxicity. This will bring the panel from 19 variants to a total of 20 variants.
This change reflects our updated internal clinical validation and recent updates to the CPIC Guidelines for Fluoropyrimidines and DPYD.
The clinical impact of the inclusion of HAPB3 is an expected increase in the frequency of patients requiring dose modulation or for whom fluoropyrimidine (including 5-FU or capecitabine) based therapy is contraindicated by 0.5-1% above the existing rate. No other aspect of the ToxNav® assay will be impacted by this change.
It is incredibly exciting to be on the forefront of genomics and its roll out into the clinic. The team at OCB have previously demonstrated that our ToxNav® algorithm provided clinically meaningful information that altered the way clinicians prescribed fluoropyrimidine based chemotherapy for patients with colorectal cancer. The inclusion of HAPB3 in the ToxNav® panel casts the ‘genetic net’ even wider to ensure that OCB can make cancer treatment pathways as safe as possible.
If you would like to know more about this change or anything else related to ToxNav®, please reach out to one of the team.